Platelet GP IIb/IIIa receptor inhibitors in diabetics undergoing PCI using stents

Ivan P. Casserly; Marco Roffi; David J. Moliterno

Platelet GP IIb/IIIa receptor inhibitors in diabetics undergoing PCI using stents

Ivan P. Casserly, Marco Roffi, David J. Moliterno

Research output: Contribution to journal › Review article › peer-review

Abstract

We examined the outcomes of the diabetic population in the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) to test whether clinical outcomes with tirofiban were similar to abciximab. Glycoprotein (GP) IIb/IIIa inhibition with tirofiban and abciximab was largely associated with similar clinical outcomes in this important patient subset. The similar rates of 6-month target-vessel revascularization and 1-year mortality in the two treatment groups suggest that the non-GP IIb/IIIa actions of abciximab are not associated with an appreciable clinical benefit in diabetic patients.

Original language	English
Pages (from-to)	9-13
Number of pages	5
Journal	Cardiology Review
Volume	20
Issue number	1
State	Published - Jan 2003

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{c49aa08ca2b04a109575633537f1610b,

title = "Platelet GP IIb/IIIa receptor inhibitors in diabetics undergoing PCI using stents",

abstract = "We examined the outcomes of the diabetic population in the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) to test whether clinical outcomes with tirofiban were similar to abciximab. Glycoprotein (GP) IIb/IIIa inhibition with tirofiban and abciximab was largely associated with similar clinical outcomes in this important patient subset. The similar rates of 6-month target-vessel revascularization and 1-year mortality in the two treatment groups suggest that the non-GP IIb/IIIa actions of abciximab are not associated with an appreciable clinical benefit in diabetic patients.",

author = "Casserly, {Ivan P.} and Marco Roffi and Moliterno, {David J.}",

year = "2003",

month = jan,

language = "English",

volume = "20",

pages = "9--13",

number = "1",

}

TY - JOUR

T1 - Platelet GP IIb/IIIa receptor inhibitors in diabetics undergoing PCI using stents

AU - Casserly, Ivan P.

AU - Roffi, Marco

AU - Moliterno, David J.

PY - 2003/1

Y1 - 2003/1

N2 - We examined the outcomes of the diabetic population in the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) to test whether clinical outcomes with tirofiban were similar to abciximab. Glycoprotein (GP) IIb/IIIa inhibition with tirofiban and abciximab was largely associated with similar clinical outcomes in this important patient subset. The similar rates of 6-month target-vessel revascularization and 1-year mortality in the two treatment groups suggest that the non-GP IIb/IIIa actions of abciximab are not associated with an appreciable clinical benefit in diabetic patients.

AB - We examined the outcomes of the diabetic population in the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) to test whether clinical outcomes with tirofiban were similar to abciximab. Glycoprotein (GP) IIb/IIIa inhibition with tirofiban and abciximab was largely associated with similar clinical outcomes in this important patient subset. The similar rates of 6-month target-vessel revascularization and 1-year mortality in the two treatment groups suggest that the non-GP IIb/IIIa actions of abciximab are not associated with an appreciable clinical benefit in diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=0037247645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037247645&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0037247645

SN - 1092-6607

VL - 20

SP - 9

EP - 13

JO - Cardiology Review

JF - Cardiology Review

IS - 1

ER -

Platelet GP IIb/IIIa receptor inhibitors in diabetics undergoing PCI using stents

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this